Animalcare Group PLC
LSE:ANCR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (2), the stock would be worth GBX232.98 (30% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.8 | GBX332 |
0%
|
| 3-Year Average | 2 | GBX232.98 |
-30%
|
| 5-Year Average | 2.1 | GBX243.66 |
-27%
|
| Industry Average | 0 | GBX4.75 |
-99%
|
| Country Average | 0 | GBX2.46 |
-99%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
GBX189.5m
|
/ |
Jul 2025
£81.1m
|
= |
|
|
GBX189.5m
|
/ |
Dec 2025
£90m
|
= |
|
|
GBX189.5m
|
/ |
Dec 2026
£94.9m
|
= |
|
|
GBX189.5m
|
/ |
Dec 2027
£99.8m
|
= |
|
|
GBX189.5m
|
/ |
Dec 2028
£108.9m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Animalcare Group PLC
LSE:ANCR
|
229m GBP | 2.8 | 76.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 14 | 44.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 5.7 | 26.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 4.7 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 4.3 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 2.4 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 767.5 |
Other Multiples
Animalcare Group PLC
Glance View
Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire. The company went IPO on 2008-01-15. The firm is focused on developing and commercializing prescription and over-the-counter pharmaceutical products. The firm operates in three categories within the veterinary market, which includes Companion Animals, Equine and Production Animals. The company manages international supply chain, including specialist veterinary wholesalers and distributors. The firm develops, supplies and markets products and services to the veterinary profession. The company focuses on therapeutic areas, which includes pain management, dermatology and anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.
